We are live on
!
Find out more
HCM
Hillman Capital Management Portfolio holdings
AUM
$144M
1-Year Est. Return
7.02%
This Fund
S&P 500
This Quarter
Est. Return
-13.18%
1 Year Est. Return
+7.02%
3 Year Est. Return
+20.27%
5 Year Est. Return
+21.27%
10 Year Est. Return
–
AUM
$275M
AUM Growth
-$39.7M
(-13%)
Cap. Flow
+$7.45M
Cap. Flow
% of AUM
2.71%
Top 10 Holdings %
Top 10 Hldgs %
35%
Holding
50
New
2
Increased
43
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$7.47M |
| 2 |
Warner Bros
WBD
|
+$4.68M |
| 3 |
Salesforce
CRM
|
+$1.49M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$1.41M |
| 5 |
Microsoft
MSFT
|
+$1.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$9.91M |
| 2 |
MMP
Magellan Midstream Partners, L.P.
MMP
|
+$7.38M |
| 3 |
Becton Dickinson
BDX
|
+$129K |
| 4 |
Merck
MRK
|
+$123K |
| 5 |
CVS Health
CVS
|
+$16.9K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.33% |
| 2 | Technology | 16.2% |
| 3 | Consumer Staples | 13.92% |
| 4 | Communication Services | 13.79% |
| 5 | Financials | 10.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
K
1
DELISTED
Kellanova
K
| $11.1M | 4.05% |
166,371
+884
| +0.5% | +$57.4K |
|
2
AT&T
T
$167B
| $10.5M | 3.8% |
499,646
+37,203
| +8% | +$742K |
|
3
Kraft Heinz
KHC
$29B
| $10.4M | 3.78% |
272,500
+1,277
| +0.5% | +$51.1K |
|
4
GSK
GSK
$101B
| $10.3M | 3.75% |
189,467
+916
| +0.5% | +$50.6K |
|
|
5
Microsoft
MSFT
$3.66T
| $9.26M | 3.36% |
36,047
+4,213
| +13% | +$1.14M |
|
6
Enterprise Products Partners
EPD
$81.9B
| $9.24M | 3.36% |
379,108
+1,520
| +0.4% | +$40K |
|
|
7
CVS Health
CVS
$121B
| $9.02M | 3.28% |
97,310
-173
| -0.2% | -$16.9K |
|
|
8
Merck
MRK
$330B
| $8.95M | 3.25% |
98,114
-1,385
| -1% | -$123K |
|
9
Wells Fargo
WFC
$269B
| $8.79M | 3.19% |
224,509
+25,601
| +13% | +$1.12M |
|
10
Biogen
BIIB
$30.8B
| $8.77M | 3.19% |
43,019
+340
| +0.8% | +$69.5K |
|
11
AB InBev
BUD
$156B
| $8.53M | 3.1% |
158,102
+2,518
| +2% | +$141K |
|
12
Plains All American Pipeline
PAA
$16.4B
| $8.53M | 3.1% |
868,298
+4,503
| +0.5% | +$48.8K |
|
13
Conagra Brands
CAG
$7.19B
| $7.64M | 2.77% |
223,016
+1,299
| +0.6% | +$44.2K |
|
14
ASML
ASML
$700B
| $7.59M | 2.76% |
15,953
+1,362
| +9% | +$760K |
|
15
Intel
INTC
$517B
| $7.58M | 2.75% |
202,473
+24,961
| +14% | +$1.08M |
|
16
DuPont de Nemours
DD
$19.6B
| $7.55M | 2.74% |
108,171
+6,301
| +6% | +$516K |
|
17
RTX Corp
RTX
$301B
| $7.11M | 2.58% |
73,993
+422
| +0.6% | +$40.6K |
|
18
Verizon
VZ
$195B
| $7.1M | 2.58% |
139,926
+874
| +0.6% | +$44.2K |
|
19
Simon Property Group
SPG
$71.1B
| $7.09M | 2.57% |
74,661
+921
| +1% | +$106K |
|
|
20
Salesforce
CRM
$158B
| $6.97M | 2.53% |
42,242
+8,427
| +25% | +$1.49M |
|
|
21
Warner Bros
WBD
$69B
| $6.72M | 2.44% |
500,844
+252,354
| +102% | +$4.68M |
|
22
Boeing
BA
$183B
| $6.71M | 2.44% |
49,062
+2,464
| +5% | +$363K |
|
|
23
Lam Research
LRCX
$410B
| $6.69M | 2.43% |
+156,880
| New | +$7.47M |
|
|
24
Becton Dickinson
BDX
$49.8B
| $6.65M | 2.41% |
26,958
-508
| -2% | -$129K |
|
25
Amazon
AMZN
$2.9T
| $6.63M | 2.41% |
62,398
+1,738
| +3% | +$217K |
|
Similar funds
AL
KK
GGI
I
AGM
PU
TP
12CM
Hillman Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Hillman Capital Management held 50 positions worth $275M, down 13% from $315M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Hillman Capital Management's Q2 2022 filing shows 2 new, 43 increased, 3 reduced and 2 closed positions. Its largest new stake was Lam Research: 156,880 shares worth $6.69M. The largest sale was Bristol-Myers Squibb, an estimated $9.91M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, down from 20% a quarter earlier, followed by Technology and Consumer Staples.
- Hillman Capital Management's largest Q2 2022 buy was Lam Research: 156,880 shares worth $6.69M.
- Hillman Capital Management added most to Warner Bros in Q2 2022, an estimated $4.68M increase.
- Hillman Capital Management's biggest Q2 2022 reduction was Becton Dickinson, cutting an estimated $129K.
- Hillman Capital Management fully exited Bristol-Myers Squibb in Q2 2022, selling an estimated $9.91M.
- Hillman Capital Management's ten largest holdings make up 35% of its $275M portfolio in Q2 2022.
- Hillman Capital Management opened 2 new positions and closed 2 in Q2 2022.
- Hillman Capital Management's portfolio value fell 13% quarter-over-quarter to $275M.
Based on Hillman Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.